Telix to Acquire QSAM Biosciences to Enhance its Oncology Segment

Share this


Telix to Acquire QSAM Biosciences to Enhance its Oncology Segment


  • Telix signed a definitive agreement to acquire QSAM Biosciences for its lead asset Samarium-153-DOTMP (153Sm-DOTMP) a product developed for the treatment of metastatic bone cancer. The transaction details remain undisclosed
  • 153Sm-DOTMP is a kit-based bone-seeking targeted radiopharmaceutical product that utilizes a chelating agent to deliver a formulation of Samarium-153 radioisotope
  • In pre-clinical & early clinical trials 153Sm-DOTMP has depicted significant safety, efficacy & future commercial utility with the potential to deliver significant improvements on prior bone-seeking agents in the treatment and management of late-stage metastatic disease. Earlier, 153Sm-DOTMP the US FDA’s ODD & RPDD for the treatment of osteosarcoma

Ref: Telix Pharmaceuticals | Image: Telix Pharmaceuticals

Related News:- Telix Presented P-III Results from TLX250-CDx for Kidney Cancer Imaging Study at the ASCO GU 2023

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions